<?xml version='1.0' encoding='utf-8'?>
<document id="30972148"><sentence text="Comparing the Medicaid Prospective Drug Utilization Review Program Cost-Savings Methods Used by State Agencies in 2015 and 2016." /><sentence text="The Medicaid Drug Utilization Review (DUR) program is a 2-phase process conducted by Medicaid state agencies" /><sentence text=" The first phase is a prospective DUR process and involves electronically monitoring prescription drug claims to identify prescription-related problems, such as therapeutic duplication, contraindications, incorrect dosage, or duration of treatment" /><sentence text=" The second phase is a retrospective DUR involving ongoing, periodic examinations of claims data to identify patterns of fraud, abuse, underutilization, drug-drug interaction, and medically unnecessary care, and implement corrective actions when needed" /><sentence text=" The Centers for Medicare &amp; Medicaid Services requires each state to measure the prescription drug cost-savings generated from its DUR programs annually, but it provides no methodology for doing so" /><sentence text=" An earlier article compared the methodologies used by states to measure cost-savings in their retrospective DUR program in fiscal years 2014 and 2015" /><sentence text="" /><sentence text="To describe and synthesize the methodologies used by states to measure cost-savings using their Medicaid prospective DUR program in federal fiscal years 2015 and 2016" /><sentence text="" /><sentence text="For each state, we downloaded from Medicaid's website the cost-savings methodologies included in the Medicaid DUR 2015 and 2016 reports" /><sentence text=" We then reviewed and synthesized the reports" /><sentence text=" Methods described by the states were classified into a unique group based on the methodology used, except for Arkansas and Connecticut, which were classified in more than 1 category for the same period" /><sentence text="" /><sentence text="Currently, 3 different methodologies are being used by states" /><sentence text=" In 2015 and 2016, the most common methodology used (by 18 states) was the calculation of total claim rejections and subtracting claim resubmissions at the amount actually paid" /><sentence text=" The comparisons of DUR program cost-savings among states are unreliable, because the states lack a common methodology in the way they measure their performance" /><sentence text="" /><sentence text="Considering the lack of methodologic consistency among states in measuring the savings in the Medicaid DUR program shown in this analysis, the federal government must lead an effort to define a unique methodology to measure cost-savings in its entire DUR program" /><sentence text=" This will help to improve the measure of savings among states and understand how this program is performing in that matter" /><sentence text="" /></document>